Zhejiang Jiuzhou Pharmaceutical's wholly-owned subsidiary has been recognized as a high-tech enterprise.
Jiuzhou Pharmaceutical (603456.SH) announcement, according to the national high-tech enterprise recognition management work leading group office...
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary Ruibo (Hangzhou) Medical Technology Co., Ltd. (referred to as "Ruibo Hangzhou") has obtained the certification of a high-tech enterprise. The certificate number is GR202433008949, issued on December 6, 2024, and valid for three years.
According to national regulations, Ruibo Hangzhou will enjoy related tax preferential policies for high-tech enterprises for three years (2024-2026) after obtaining the certification, with a tax rate of 15% for corporate income tax.
Related Articles

Ningbo Shanshan (600884.SH) may see a change in its controlling shareholder to Wanwei Group.

Broad strategy: A-shares may usher in a new round of upward cycle in the future.

Zhejiang Tenchen Controls' subsidiary has become a supplier of passenger car seats for a domestic automotive company in China.
Ningbo Shanshan (600884.SH) may see a change in its controlling shareholder to Wanwei Group.

Broad strategy: A-shares may usher in a new round of upward cycle in the future.

Zhejiang Tenchen Controls' subsidiary has become a supplier of passenger car seats for a domestic automotive company in China.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


